CAJ | 학술논문

目的探讨宫颈癌术后螺旋断层放疗(helical tomotherapy,HT)与常规调强放疗(intensity-modulated radiation therapy, IMRT)近期疗效.方法228例宫颈癌术后放疗患者,HT组153例、IMRT组75例.盆腔淋巴引流区照射46-50.4Gy/23-28F;高危淋巴引流区60Gy/25-28F;残留肿瘤及肿大淋巴结64-66Gy/25-28F.阴道后装放疗2-3次,每次黏膜表面剂量8Gy.采用RTOG(radiation therapy oncology group)和EROTC(European organization for research on treatment of cancer)评分标准评价直肠和膀胱放疗反应及1-3年生存率.结果放疗期间HT组和IMRT组1级直肠反应为28.76%和42.67%(χ2=4.381, P=0.036);膀胱反应为10.46%和17.33%(χ2=2.143,P=0.143),两组均无≥2级急性放疗反应发生.HT组和IMRT组1、2、3年生存率分别为94.22%、89.13%、85.21%和93.86%、81.84%、71.11%(P=0.327).结论宫颈癌术后放疗急性反应HT组明显低于IMRT组,1-3年生存率两组差异无统计学意义.
목적탐토궁경암술후라선단층방료(helical tomotherapy,HT)여상규조강방료(intensity-modulated radiation therapy, IMRT)근기료효.방법228례궁경암술후방료환자,HT조153례、IMRT조75례.분강림파인류구조사46-50.4Gy/23-28F;고위림파인류구60Gy/25-28F;잔류종류급종대림파결64-66Gy/25-28F.음도후장방료2-3차,매차점막표면제량8Gy.채용RTOG(radiation therapy oncology group)화EROTC(European organization for research on treatment of cancer)평분표준평개직장화방광방료반응급1-3년생존솔.결과방료기간HT조화IMRT조1급직장반응위28.76%화42.67%(χ2=4.381, P=0.036);방광반응위10.46%화17.33%(χ2=2.143,P=0.143),량조균무≥2급급성방료반응발생.HT조화IMRT조1、2、3년생존솔분별위94.22%、89.13%、85.21%화93.86%、81.84%、71.11%(P=0.327).결론궁경암술후방료급성반응HT조명현저우IMRT조,1-3년생존솔량조차이무통계학의의.